GHRH analogue for somatotropic axis research.
Tesamorelin is a stabilized analogue of growth-hormone-releasing hormone used in research of the somatotropic axis.
Binds GHRH receptors on pituitary somatotrophs, stimulating endogenous growth-hormone pulsatility under physiological feedback.
Peptide engages target receptor with high affinity.
Downstream intracellular pathways activate.
Gene expression and protein synthesis shift.
Measurable change in the studied biomarker.
Phase 3 RCT of tesamorelin 2 mg/day on visceral adipose tissue (VAT) measured by CT.
−15.2% VAT vs. +5.0% placebo with concurrent IGF-1 normalization.
Randomized study using MRS quantification of hepatic and visceral fat.
Significant reduction in liver fat fraction and VAT vs. placebo.
Assessed glycemic safety of tesamorelin in patients with established T2D.
Transient IGF-1 rise without sustained glycemic deterioration.
Lyophilized at -20°C. After reconstitution, 2–8°C, use within 14 days.
Strictly for in-vitro laboratory and research investigations.
Not approved for diagnostic, therapeutic, or veterinary application.
Handling restricted to licensed researchers and laboratory staff.
Warning — Tesamorelin is supplied solely for legitimate laboratory research. Any administration to humans or animals is strictly prohibited and may violate federal, state, or local law. By purchasing, the researcher accepts full responsibility for safe handling, storage, and lawful use.
